BG
XLRN

BlackRock Group’s Acceleron Pharma XLRN Stock Holding History

BlackRock Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$7.06M Buy
276,525
+87,794
+47% +$2.78M ﹤0.01% 1013
2016
Q3 		$6.83M Sell
188,731
-2,313
-1% -$76.6K ﹤0.01% 1008
2016
Q2 		$6.49M Sell
191,044
-129
-0.1% -$4.19K ﹤0.01% 1004
2016
Q1 		$5.04M Buy
191,173
+74,285
+64% +$2.16M ﹤0.01% 1079
2015
Q4 		$5.7M Buy
116,888
+846
+0.7% +$30.4K ﹤0.01% 1063
2015
Q3 		$2.89M Buy
116,042
+5,714
+5% +$172K ﹤0.01% 1306
2015
Q2 		$3.49M Buy
110,328
+10,275
+10% +$332K ﹤0.01% 1276
2015
Q1 		$3.81M Buy
100,053
+10,752
+12% +$428K ﹤0.01% 1208
2014
Q4 		$3.48M Buy
89,301
+34,675
+63% +$1.21M ﹤0.01% 1254
2014
Q3 		$1.65M Buy
54,626
+526
+1% +$14.8K ﹤0.01% 1508
2014
Q2 		$1.84M Sell
54,100
-807
-1% -$27K ﹤0.01% 1505
2014
Q1 		$1.9M Buy
54,907
+12,807
+30% +$578K ﹤0.01% 1605
2013
Q4 		$1.67M Buy
+42,100
New +$1.02M ﹤0.01% 1655

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

BlackRock Group's XLRN Position: Q4 2016 in Review

BlackRock Group increased its Acceleron Pharma (XLRN) stake by 47% in Q4 2016, buying an estimated $2.78M and bringing the position to 276,525 shares worth $7.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1013.

BlackRock Group first reported a position in XLRN in Q4 2013 and has held it in 13 quarters since. 146 funds tracked by Wall St. Rank hold XLRN as of Q4 2016.

  • BlackRock Group held 276,525 shares of Acceleron Pharma worth $7.06M as of Q4 2016.
  • BlackRock Group bought 87,794 Acceleron Pharma shares in Q4 2016, an estimated $2.78M.
  • Acceleron Pharma made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1013 holding.
  • BlackRock Group first reported a position in Acceleron Pharma in Q4 2013 and has held it in 13 quarters since.
  • 146 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.